Federal Circuit: Skepticism of FDA Supports Finding of Nonobviousness and Patent Eligibility Not Within Scope of Appeal of an IPR

Apr 30, 2019

Reading Time : 2 min

The claims of the ’209 Patent were challenged in three petitions for inter partes review (IPR), but in each case the Board concluded that there was no motivation to combine the asserted prior art and that “skepticism of others,” namely the FDA, supported a finding of nonobviousness. On appeal, the Federal Circuit held that the Board’s findings were supported by the evidence and affirmed the Board’s final written decisions.

As to motivation to combine, the Federal Circuit agreed with the Board that one of the prior art references was limited to cardiovascular concerns and only generally mentioned cancer. As such, there was no motivation to combine references across fields of treatment. With respect to the Board’s findings regarding “skepticism of others,” the patent challengers argued on appeal that the FDA’s concern regarding the claimed treatment was insufficient because the FDA had allowed the patent owner to go forward with clinical trials. The Federal Circuit disagreed and noted that there is a range as to what constitutes skepticism—from a belief an invention is impossible to a belief that it is unlikely. In this case, the Federal Circuit found that the FDA’s concerns expressed during the clinical trials amounted to skepticism.

Finally, on appeal the patent challengers argued that the claims of the ’209 Patent were not directed to patentable subject matter and that, because patent eligibility is a question of law, this was an issue that could be raised properly on appeal. The Federal Circuit disagreed stating that Congress expressly limited IPRs to grounds that can be raised under 35 U.S.C. §§ 102 and 103. Thus, because patent eligibility arises under § 101, the Federal Circuit held that it cannot be addressed on appeal of an IPR.

Practice Tip: In an IPR, a petitioner should explain thoroughly the motivation to combine the prior art references, especially when those references may be viewed as relating to different fields, even if those fields seem closely related. Moreover, “skepticism of others”—as a secondary consideration of nonobviousness—may not require evidence of technical impossibility, but a simple showing of concern or surprise may suffice.

Neptune Generics, LLC v. Eli Lilly & Company, 2018-1257, 2018-1258 (Fed. Cir. Apr. 26, 2019); Mylan Laboratories Limited, et al. v. Eli Lilly & Company, 2018-1288, 2018-1290 (Fed. Cir. Apr. 26, 2019).

Share This Insight

Previous Entries

IP Newsflash

April 1, 2025

The District of Delaware recently denied in part a motion to compel production of documents and testimony between a patentee and potential investors, valuation firms and an international bank based on the common interest exception. In so doing, the court reaffirmed that disclosure of privileged information to third parties will generally waive privilege unless it can be shown that the parties’ interests are identical and the communications are legal, not solely commercial.

...

Read More

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.